Initial Press Release. Cerecor Bolsters Clinical Pipeline with Acquisition of Phase 2-ready Kappa Opioid Receptor Antagonist from ▇▇▇ ▇▇▇▇▇ and Company
Appears in 2 contracts
Sources: Exclusive Patent and Know How License Agreement (Cerecor Inc.), Exclusive Patent and Know How License Agreement (Cerecor Inc.)